1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
TTK Healthcare Limited

TTK Healthcare Limited

TTKHLTCARE.NS
TTK Healthcare LimitedIN flagNational Stock Exchange of India
920.40
INR
+1.35
- -
13.01BMarket Cap
TTK Healthcare Limited
TTKHLTCARE.NS
(National Stock Exchange of India)

Recent

price

920.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
400.36
455.01
491.77
535.1
621.36
662.89
676.42
407.61
443.15
456.23
334.91
421.85
509.69
529.11
564.49
- -
580.3
Revenue per Share
18.96
20.13
18.29
15.95
20.8
29.19
24.13
12.86
17.25
8.72
32.87
29.43
452.73
44.47
57.79
- -
44.64
Basic EPS, GAAP
20.78
2.33
21.49
-3.58
-12.58
26.41
15.97
14.77
9.19
5.38
67.01
27.95
-25.84
-10.85
-11.9
- -
- -
Free Cash Flow per Basic Share
4.08
4.65
4.65
4.68
4.68
5.42
6
3.31
6.03
6.03
3
6
10
10
10
- -
- -
Dividend per Share
44.56
57.97
69.72
79.31
92.12
108.29
123.73
87.62
98.18
99.49
128.69
152.21
595.12
628.99
675.35
- -
- -
Book Value per Share
97.16
112.36
126.01
137.28
151.91
181.67
202.34
164.47
177.7
176.05
208.42
233.22
674.7
708.36
753.75
- -
- -
Tangible Book Value per Share
8
8
8
8
8
8
8
14
14
14
14
14
14
14
14
- -
14
Basic Weighted Avg Shares
3,109
3,534
3,819
4,156
4,825
5,148
5,253
5,760
6,262
6,446
4,732
5,961
7,202
7,476
7,976
8,544
8,200
Sales/Revenue/Turnover
6.54
6.13
4.67
4.24
5.02
6.52
5.11
4.88
5.77
2.33
1.4
1.59
2.65
3.34
3.38
2.07
2.7
Operating Margin (%)
20
24
27
32
61
72
119
152
147
144
137
132
129
131
83
88
85
Depreciation Expense
147
156
142
124
162
227
187
182
244
123
464
416
6,397
628
817
657
631
Net Income, GAAP
33.52
33.63
34.31
37
38.65
36.2
35.77
39.74
37.92
36.58
- -
25.47
27.53
25.3
24.62
20.45
25.95
Effective Tax Rate (%)
4.73
4.42
3.72
2.98
3.35
4.4
3.57
3.15
3.89
1.91
9.81
6.98
88.83
8.41
10.24
7.69
7.69
Profit Margin (%)
405
517
545
571
370
223
469
881
1,146
1,262
1,861
2,280
8,553
8,758
8,930
10,117
- -
Working Capital
6
5
6
159
160
11
9
7
3
13
12
13
12
8
18
20
- -
LT Debt
757
877
982
1,069
1,183
1,413
1,575
2,330
2,514
2,490
2,946
3,296
9,534
10,009
10,650
11,149
- -
Total Equity
16.13
14.59
10.15
8.4
9.77
12.51
9.57
7.32
7.94
3.4
- -
2.12
2.07
1.86
1.91
1.26
- -
Return on Invested Capital (%)
25.16
31.14
22.61
16.73
17.75
20.97
17.08
14.42
15.59
8.48
- -
20.08
116.42
7.22
8.8
6.68
198.54
Return on Capital (%)
29.66
39.26
28.65
21.41
24.27
29.12
20.8
16.52
18.57
8.82
28.81
20.96
121.16
7.27
8.86
6.7
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
224
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
18
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
14
- -
Market Capitalization
19,890
16,816
18,054

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
11,039
- -
Cash, Cash Equivalents & STI
- -
8,551
- -
Accounts Receivable, Net
- -
905
- -
Inventories
- -
1,086
- -
Total Current Liabilities
- -
2,109
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
224
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
30.19%
43.44%
4.68%
Free Cash Flow
85.61%
-47.76%
60.27%
Net Income, GAAP
158.93%
269.59%
-19.57%
Sales/Revenue/Turnover
6.12%
12.88%
7.11%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,021
1,858
1,838
1,759
7,476
2025
2,079
1,985
2,047
1,904
7,976
2026
2,264
2,093
2,180
- -
8,544

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11.09
11.33
9.13
- -
44.47
2025
22.35
12.17
11.84
11.43
57.79
2026
9.2
7.45
15.4
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
10
2025
- -
- -
- -
- -
10
2026
- -
- -
- -
- -
- -
Similar Companies
Johnson & Johnson (JNJ.DE)
Sanofi India Limited (SANOFI.BO)
NGL Fine-Chem Limited (NGLFINE.BO)
Eli Lilly and Company (LLY)
AbbVie Inc. (4AB.DE)
Metacare Co., Ltd. (118000.KS)
Business
TTK Healthcare Limited (TTKHLTCARE.NS) manufactures and markets a diverse portfolio of healthcare and personal care products, including condoms under the brands KAREX, Ninja, and Holiday; pregnancy test kits under the Preganews brand; and scalp care and hygiene products under the World's Best and iSage brands. The company also provides diabetic foot care devices through Podfeet, sexual wellness gels and lubricants via Sara brands, and safety razors and blades under the Laser brand; additionally, it offers baby wipes under the TTK Baby Soft brand and distributes international brands such as Lifestyles condoms and Nua treatments in India. TTK Healthcare operates primarily in the consumer healthcare and personal care segments, targeting individual consumers through retail channels across India, with exports to select international markets. Founded in 1994 and headquartered in Chennai, India, the company is part of the TTK Group and focuses on branded consumer products in sexual wellness, women's health, hygiene, and grooming categories. Its product offerings emphasize affordability, quality, and innovation to serve urban and rural markets in India. The company maintains manufacturing facilities in India and leverages a widespread distribution network for market penetration. In recent developments, TTK Healthcare expanded its product portfolio with the launch of new variants in its razor and blade lines under the Laser brand, enhancing its grooming segment presence as of 2024. The company also strengthened its sexual wellness offerings through strategic distribution partnerships for global brands like Lifestyles, amid growing market demand in India. No major acquisitions, funding rounds, or reorganizations have been reported in the last 1-2 years, with operations remaining stable under the TTK Group structure.